{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T06:41:25Z","timestamp":1789195285467,"version":"build-2803163510"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T00:00:00Z","timestamp":1495411200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12016-017-8611-x","type":"journal-article","created":{"date-parts":[[2017,5,22]],"date-time":"2017-05-22T07:47:34Z","timestamp":1495439254000},"page":"224-233","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["MicroRNAs: New Therapeutic Targets for Familial Hypercholesterolemia?"],"prefix":"10.1007","volume":"54","author":[{"given":"Amir Abbas","family":"Momtazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6690-6874","authenticated-orcid":false,"given":"Maciej","family":"Banach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Pirro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan A.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sahebkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,5,22]]},"reference":[{"issue":"1","key":"8611_CR1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40119-015-0037-z","volume":"4","author":"O Najam","year":"2015","unstructured":"Najam O, Ray KK (2015) Familial hypercholesterolemia: a review of the natural history, diagnosis, and management. Cardiology and therapy 4(1):25\u201338","journal-title":"Cardiology and therapy"},{"key":"8611_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosissup.2016.10.001","volume":"22","author":"Collaboration, E.A.S.F.H.S","year":"2016","unstructured":"Collaboration, E.A.S.F.H.S et al (2016) Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: rationale and design of the global EAS familial Hypercholesterolaemia studies collaboration. Atheroscler Suppl 22:1\u201332","journal-title":"Atheroscler Suppl"},{"issue":"1","key":"8611_CR3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.atherosclerosis.2015.09.021","volume":"243","author":"AJ Vallejo-Vaz","year":"2015","unstructured":"Vallejo-Vaz AJ et al (2015) Familial hypercholesterolaemia: a global call to arms. Atherosclerosis 243(1):257\u2013259","journal-title":"Atherosclerosis"},{"issue":"2","key":"8611_CR4","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cjca.2012.11.032","volume":"29","author":"TJ Anderson","year":"2013","unstructured":"Anderson TJ et al (2013) 2012 update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 29(2):151\u2013167","journal-title":"Can J Cardiol"},{"issue":"1","key":"8611_CR5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12929-016-0256-1","volume":"23","author":"R Henderson","year":"2016","unstructured":"Henderson R et al (2016) The genetics and screening of familial hypercholesterolaemia. J Biomed Sci 23(1):39","journal-title":"J Biomed Sci"},{"issue":"32","key":"8611_CR6","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","volume":"35","author":"M Cuchel","year":"2014","unstructured":"Cuchel M et al (2014) Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 35(32):2146\u20132157","journal-title":"Eur Heart J"},{"issue":"45","key":"8611_CR7","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","volume":"34","author":"BG Nordestgaard","year":"2013","unstructured":"Nordestgaard BG et al (2013) Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease. Eur Heart J 34(45):3478\u20133490","journal-title":"Eur Heart J"},{"issue":"25","key":"8611_CR8","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP et al (2015) Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372(25):2387\u20132397","journal-title":"N Engl J Med"},{"issue":"39","key":"8611_CR9","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL et al (2016) 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J 37(39):2999\u20133058","journal-title":"Eur Heart J"},{"issue":"1","key":"8611_CR10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2017.64712","volume":"13","author":"M Banach","year":"2017","unstructured":"Banach M et al (2017) PoLA\/CFPiP\/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Arch Med Sci 13(1):1\u201345","journal-title":"Arch Med Sci"},{"issue":"3","key":"8611_CR11","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1161\/CIRCGENETICS.116.001381","volume":"9","author":"EM Goma de","year":"2016","unstructured":"de Goma EM et al (2016) Treatment gaps in adults with heterozygous familial hypercholesterolemia in the United States: data from the CASCADE-FH Registry. Circ Cardiovasc Genet 9(3):240\u2013249","journal-title":"Circ Cardiovasc Genet"},{"issue":"1","key":"8611_CR12","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.atherosclerosis.2007.06.028","volume":"197","author":"AD Marais","year":"2008","unstructured":"Marais AD et al (2008) A dose-titration and comparative study of rosuvastatin and atorvastatin in patients with homozygous familial hypercholesterolaemia. Atherosclerosis 197(1):400\u2013406","journal-title":"Atherosclerosis"},{"issue":"2","key":"8611_CR13","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0021-9150(97)00168-8","volume":"135","author":"FJ Raal","year":"1997","unstructured":"Raal FJ et al (1997) Expanded-dose simvastatin is effective in homozygous familial hypercholesterolaemia. Atherosclerosis 135(2):249\u2013256","journal-title":"Atherosclerosis"},{"issue":"21","key":"8611_CR14","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000018744.58460.62","volume":"105","author":"C Gagn\u00e9","year":"2002","unstructured":"Gagn\u00e9 C et al (2002) Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105(21):2469\u20132475","journal-title":"Circulation"},{"key":"8611_CR15","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.phrs.2017.03.023","volume":"120","author":"AA Momtazi","year":"2017","unstructured":"Momtazi AA et al (2017) Regulation of PCSK9 by nutraceuticals. Pharmacol Res 120:157\u2013169","journal-title":"Pharmacol Res"},{"issue":"5696","key":"8611_CR16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.1105136","volume":"306","author":"EP Consortium","year":"2004","unstructured":"Consortium EP (2004) The ENCODE (ENCyclopedia of DNA elements) project. Science 306(5696):636\u2013640","journal-title":"Science"},{"issue":"1","key":"8611_CR17","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.chembiol.2011.12.008","volume":"19","author":"JC Burnett","year":"2012","unstructured":"Burnett JC, Rossi JJ (2012) RNA-based therapeutics: current progress and future prospects. Chem Biol 19(1):60\u201371","journal-title":"Chem Biol"},{"key":"8611_CR18","doi-asserted-by":"crossref","first-page":"e252","DOI":"10.1038\/mtna.2015.23","volume":"4","author":"JK Lam","year":"2015","unstructured":"Lam JK et al (2015) siRNA versus miRNA as therapeutics for gene silencing. Molecular Therapy-Nucleic Acids 4:e252","journal-title":"Molecular Therapy-Nucleic Acids"},{"issue":"2","key":"8611_CR19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.gene.2013.12.019","volume":"538","author":"Y Deng","year":"2014","unstructured":"Deng Y et al (2014) Therapeutic potentials of gene silencing by RNA interference: principles, challenges, and new strategies. Gene 538(2):217\u2013227","journal-title":"Gene"},{"issue":"5","key":"8611_CR20","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nrg2968","volume":"12","author":"BL Davidson","year":"2011","unstructured":"Davidson BL, McCray PB (2011) Current prospects for RNA interference-based therapies. Nat Rev Genet 12(5):329\u2013340","journal-title":"Nat Rev Genet"},{"issue":"3","key":"8611_CR21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/nrg2006","volume":"8","author":"DH Kim","year":"2007","unstructured":"Kim DH, Rossi JJ (2007) Strategies for silencing human disease using RNA interference. Nat Rev Genet 8(3):173\u2013184","journal-title":"Nat Rev Genet"},{"issue":"4","key":"8611_CR22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","volume":"67","author":"N Agrawal","year":"2003","unstructured":"Agrawal N et al (2003) RNA interference: biology, mechanism, and applications. Microbiol Mol Biol Rev 67(4):657\u2013685","journal-title":"Microbiol Mol Biol Rev"},{"issue":"1","key":"8611_CR23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrc2966","volume":"11","author":"CV Pecot","year":"2011","unstructured":"Pecot CV et al (2011) RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 11(1):59\u201367","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"8611_CR24","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.tcb.2006.12.007","volume":"17","author":"RS Pillai","year":"2007","unstructured":"Pillai RS, Bhattacharyya SN, Filipowicz W (2007) Repression of protein synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17(3):118\u2013126","journal-title":"Trends Cell Biol"},{"issue":"4","key":"8611_CR25","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.molcel.2006.01.031","volume":"21","author":"CP Petersen","year":"2006","unstructured":"Petersen CP et al (2006) Short RNAs repress translation after initiation in mammalian cells. Mol Cell 21(4):533\u2013542","journal-title":"Mol Cell"},{"issue":"36","key":"8611_CR26","doi-asserted-by":"crossref","first-page":"4141","DOI":"10.1200\/JCO.2013.55.0376","volume":"32","author":"B Schultheis","year":"2014","unstructured":"Schultheis B et al (2014) First-in-human phase I study of the liposomal RNA interference therapeutic Atu027 in patients with advanced solid tumors. J Clin Oncol 32(36):4141\u20134148","journal-title":"J Clin Oncol"},{"issue":"4","key":"8611_CR27","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","volume":"3","author":"J Tabernero","year":"2013","unstructured":"Tabernero J et al (2013) First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 3(4):406\u2013417","journal-title":"Cancer Discov"},{"issue":"12","key":"8611_CR28","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1038\/gt.2011.79","volume":"18","author":"AG Bader","year":"2011","unstructured":"Bader AG et al (2011) Developing therapeutic microRNAs for cancer. Gene Ther 18(12):1121\u20131126","journal-title":"Gene Ther"},{"key":"8611_CR29","doi-asserted-by":"crossref","unstructured":"Momtazi AA et al. (2016) Curcumin as a MicroRNA regulator in cancer: a review","DOI":"10.1007\/112_2016_3"},{"issue":"19","key":"8611_CR30","doi-asserted-by":"crossref","first-page":"8800","DOI":"10.1073\/pnas.0912186107","volume":"107","author":"J DeVincenzo","year":"2010","unstructured":"DeVincenzo J et al (2010) A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci 107(19):8800\u20138805","journal-title":"Proc Natl Acad Sci"},{"issue":"9","key":"8611_CR31","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1038\/mt.2012.107","volume":"20","author":"PK Chandra","year":"2012","unstructured":"Chandra PK et al (2012) Inhibition of hepatitis C virus replication by intracellular delivery of multiple siRNAs by nanosomes. Mol Ther 20(9):1724\u20131736","journal-title":"Mol Ther"},{"issue":"4","key":"8611_CR32","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/liv.12698","volume":"35","author":"H Sendi","year":"2015","unstructured":"Sendi H et al (2015) miR-122 decreases HCV entry into hepatocytes through binding to the 3\u2032 UTR of OCLN mRNA. Liver Int 35(4):1315\u20131323","journal-title":"Liver Int"},{"key":"8611_CR33","doi-asserted-by":"crossref","unstructured":"Erdmann VA, Poller W, and Barciszewski J (2008) RNA technologies in cardiovascular medicine and research. Springer","DOI":"10.1007\/978-3-540-78709-9"},{"issue":"1","key":"8611_CR34","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"K Fitzgerald","year":"2017","unstructured":"Fitzgerald K et al (2017) A highly durable RNAi therapeutic inhibitor of PCSK9. N Engl J Med 376(1):41\u201351","journal-title":"N Engl J Med"},{"issue":"4","key":"8611_CR35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ymthe.2006.01.001","volume":"13","author":"MA Behlke","year":"2006","unstructured":"Behlke MA (2006) Progress towards in vivo use of siRNAs. Mol Ther 13(4):644\u2013670","journal-title":"Mol Ther"},{"key":"8611_CR36","doi-asserted-by":"crossref","unstructured":"Ray KK, et al. (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med","DOI":"10.1056\/NEJMoa1615758"},{"issue":"3","key":"8611_CR37","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1161\/CIRCRESAHA.111.247916","volume":"110","author":"E Rooij van","year":"2012","unstructured":"van Rooij E, Purcell AL, Levin AA (2012) Developing microRNA therapeutics. Circ Res 110(3):496\u2013507","journal-title":"Circ Res"},{"issue":"18","key":"8611_CR38","doi-asserted-by":"crossref","first-page":"7027","DOI":"10.1158\/0008-5472.CAN-10-2010","volume":"70","author":"AG Bader","year":"2010","unstructured":"Bader AG, Brown D, Winkler M (2010) The promise of microRNA replacement therapy. Cancer Res 70(18):7027\u20137030","journal-title":"Cancer Res"},{"issue":"18","key":"8611_CR39","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1016\/j.ejca.2005.06.029","volume":"41","author":"L Vidal","year":"2005","unstructured":"Vidal L et al (2005) Making sense of antisense. Eur J Cancer 41(18):2812\u20132818","journal-title":"Eur J Cancer"},{"issue":"7","key":"8611_CR40","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1261\/rna.25706","volume":"12","author":"AL Jackson","year":"2006","unstructured":"Jackson AL et al (2006) Widespread siRNA \u201coff-target\u201d transcript silencing mediated by seed region sequence complementarity. RNA 12(7):1179\u20131187","journal-title":"RNA"},{"issue":"3","key":"8611_CR41","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nmeth854","volume":"3","author":"A Birmingham","year":"2006","unstructured":"Birmingham A et al (2006) 3\u2032 UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods 3(3):199\u2013204","journal-title":"Nat Methods"},{"issue":"7","key":"8611_CR42","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1261\/rna.28106","volume":"12","author":"Y Fedorov","year":"2006","unstructured":"Fedorov Y et al (2006) Off-target effects by siRNA can induce toxic phenotype. RNA 12(7):1188\u20131196","journal-title":"RNA"},{"issue":"7092","key":"8611_CR43","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","volume":"441","author":"D Grimm","year":"2006","unstructured":"Grimm D et al (2006) Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways. Nature 441(7092):537\u2013541","journal-title":"Nature"},{"issue":"6","key":"8611_CR44","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/ijms9060978","volume":"9","author":"Z Liu","year":"2008","unstructured":"Liu Z, Sall A, Yang D (2008) MicroRNA: an emerging therapeutic target and intervention tool. Int J Mol Sci 9(6):978\u2013999","journal-title":"Int J Mol Sci"},{"issue":"12","key":"8611_CR45","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/j.bbalip.2016.03.007","volume":"1861","author":"L Goedeke","year":"2016","unstructured":"Goedeke L et al (2016) miRNA regulation of LDL-cholesterol metabolism. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1861(12):2047\u20132052","journal-title":"Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids"},{"issue":"6","key":"8611_CR46","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1093\/eurheartj\/ehp573","volume":"31","author":"G Condorelli","year":"2010","unstructured":"Condorelli G, Latronico MV, Dorn GW (2010) microRNAs in heart disease: putative novel therapeutic targets? Eur Heart J 31(6):649\u2013658","journal-title":"Eur Heart J"},{"issue":"11","key":"8611_CR47","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1042\/CS20150235","volume":"129","author":"F Martino","year":"2015","unstructured":"Martino F et al (2015) Circulating miR-33a and miR-33b are up-regulated in familial hypercholesterolaemia in paediatric age. Clin Sci 129(11):963\u2013972","journal-title":"Clin Sci"},{"issue":"3","key":"8611_CR48","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1161\/CIRCRESAHA.111.247452","volume":"110","author":"EE Creemers","year":"2012","unstructured":"Creemers EE, Tijsen AJ, Pinto YM (2012) Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 110(3):483\u2013495","journal-title":"Circ Res"},{"issue":"4","key":"8611_CR49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1570161114999160513150737","volume":"14","author":"A Sahebkar","year":"2016","unstructured":"Sahebkar A et al (2016) Editorial: microRNA-33 inhibition: a potential adjunct to statin therapy? Curr Vasc Pharmacol 14(4):321\u2013322","journal-title":"Curr Vasc Pharmacol"},{"key":"8611_CR50","doi-asserted-by":"crossref","unstructured":"Bouchie A (2013) First microRNA mimic enters clinic, Nature Research","DOI":"10.1038\/nbt0713-577"},{"issue":"3","key":"8611_CR51","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1517\/13543784.2014.867327","volume":"23","author":"Z Qiu","year":"2014","unstructured":"Qiu Z, Dai Y (2014) Roadmap of miR-122-related clinical application from bench to bedside. Expert Opin Investig Drugs 23(3):347\u2013355","journal-title":"Expert Opin Investig Drugs"},{"key":"8611_CR52","doi-asserted-by":"crossref","unstructured":"Van Rooij E and Kauppinen S (2014) Development of microRNA therapeutics is coming of age. EMBO molecular medicine, p. e201100899","DOI":"10.15252\/emmm.201100899"},{"issue":"2","key":"8611_CR53","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1073\/pnas.86.2.587","volume":"86","author":"LF Soria","year":"1989","unstructured":"Soria LF et al (1989) Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci 86(2):587\u2013591","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"8611_CR54","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/ncpcardio0836","volume":"4","author":"AK Soutar","year":"2007","unstructured":"Soutar AK, Naoumova RP (2007) Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nature clinical practice Cardiovascular medicine 4(4):214\u2013225","journal-title":"Nature clinical practice Cardiovascular medicine"},{"key":"8611_CR55","doi-asserted-by":"crossref","first-page":"e05005","DOI":"10.7554\/eLife.05005","volume":"4","author":"V Agarwal","year":"2015","unstructured":"Agarwal V et al (2015) Predicting effective microRNA target sites in mammalian mRNAs. elife 4:e05005","journal-title":"elife"},{"issue":"2","key":"8611_CR56","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.atherosclerosis.2015.08.023","volume":"242","author":"ML Alvarez","year":"2015","unstructured":"Alvarez ML et al (2015) MicroRNA-27a decreases the level and efficiency of the LDL receptor and contributes to the dysregulation of cholesterol homeostasis. Atherosclerosis 242(2):595\u2013604","journal-title":"Atherosclerosis"},{"issue":"2","key":"8611_CR57","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.atherosclerosis.2015.09.033","volume":"243","author":"L Goedeke","year":"2015","unstructured":"Goedeke L et al (2015) miR-27b inhibits LDLR and ABCA1 expression but does not influence plasma and hepatic lipid levels in mice. Atherosclerosis 243(2):499\u2013509","journal-title":"Atherosclerosis"},{"issue":"11","key":"8611_CR58","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.3980","volume":"21","author":"A Wagschal","year":"2015","unstructured":"Wagschal A et al (2015) Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis. Nat Med 21(11):1290\u20131297","journal-title":"Nat Med"},{"issue":"11","key":"8611_CR59","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/nm.3949","volume":"21","author":"L Goedeke","year":"2015","unstructured":"Goedeke L et al (2015) MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med 21(11):1280\u20131289","journal-title":"Nat Med"},{"issue":"2","key":"8611_CR60","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.atherosclerosis.2015.10.026","volume":"243","author":"H Jiang","year":"2015","unstructured":"Jiang H et al (2015) microRNA-185 modulates low density lipoprotein receptor expression as a key posttranscriptional regulator. Atherosclerosis 243(2):523\u2013532","journal-title":"Atherosclerosis"},{"key":"8611_CR61","doi-asserted-by":"crossref","unstructured":"Bai J et al. (2016) A retrospective study of NENs and miR-224 promotes apoptosis of BON-1 cells by targeting PCSK9 inhibition. Oncotarget","DOI":"10.18632\/oncotarget.14322"},{"issue":"1","key":"8611_CR62","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13046-017-0490-8","volume":"36","author":"M He","year":"2017","unstructured":"He M et al (2017) Pro-inflammation NF-kappaB signaling triggers a positive feedback via enhancing cholesterol accumulation in liver cancer cells. J Exp Clin Cancer Res 36(1):15","journal-title":"J Exp Clin Cancer Res"},{"key":"8611_CR63","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biopha.2016.01.022","volume":"78","author":"Y Li","year":"2016","unstructured":"Li Y et al (2016) MicroRNA-132 cause apoptosis of glioma cells through blockade of the SREBP-1c metabolic pathway related to SIRT1. Biomed Pharmacother 78:177\u2013184","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"8611_CR64","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.3892\/ijo.2014.2596","volume":"45","author":"H Zhang","year":"2014","unstructured":"Zhang H et al (2014) MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1. Int J Oncol 45(5):2143\u20132152","journal-title":"Int J Oncol"},{"issue":"8","key":"8611_CR65","doi-asserted-by":"crossref","first-page":"e70987","DOI":"10.1371\/journal.pone.0070987","volume":"8","author":"X Li","year":"2013","unstructured":"Li X et al (2013) MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One 8(8):e70987","journal-title":"PLoS One"},{"issue":"2","key":"8611_CR66","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1194\/jlr.M041335","volume":"55","author":"M Yang","year":"2014","unstructured":"Yang M et al (2014) Identification of miR-185 as a regulator of de novo cholesterol biosynthesis and low density lipoprotein uptake. J Lipid Res 55(2):226\u2013238","journal-title":"J Lipid Res"},{"key":"8611_CR67","doi-asserted-by":"crossref","unstructured":"Xu Y et al. (2015) A metabolic stress-inducible miR-34a-HNF4 [alpha] pathway regulates lipid and lipoprotein metabolism. Nature communications, 6","DOI":"10.1038\/ncomms8466"},{"issue":"1","key":"8611_CR68","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1743-7075-10-56","volume":"10","author":"J Soh","year":"2013","unstructured":"Soh J, Hussain MM (2013) Supplementary site interactions are critical for the regulation of microsomal triglyceride transfer protein by microRNA-30c. Nutrition & metabolism 10(1):56","journal-title":"Nutrition & metabolism"},{"issue":"7","key":"8611_CR69","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/nm.3200","volume":"19","author":"J Soh","year":"2013","unstructured":"Soh J et al (2013) MicroRNA-30c reduces hyperlipidemia and atherosclerosis in mice by decreasing lipid synthesis and lipoprotein secretion. Nat Med 19(7):892\u2013900","journal-title":"Nat Med"},{"issue":"8","key":"8611_CR70","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1172\/JCI63539","volume":"122","author":"S-H Hsu","year":"2012","unstructured":"Hsu S-H et al (2012) Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest 122(8):2871\u20132883","journal-title":"J Clin Invest"},{"issue":"2","key":"8611_CR71","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cmet.2006.01.005","volume":"3","author":"C Esau","year":"2006","unstructured":"Esau C et al (2006) miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3(2):87\u201398","journal-title":"Cell Metab"},{"issue":"1","key":"8611_CR72","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/cr.2011.158","volume":"22","author":"L Zhang","year":"2012","unstructured":"Zhang L et al (2012) Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res 22(1):107\u2013126","journal-title":"Cell Res"},{"issue":"3","key":"8611_CR73","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/MOL.0000000000000295","volume":"27","author":"NG Seidah","year":"2016","unstructured":"Seidah NG (2016) New developments in proprotein convertase subtilisin-kexin 9\u2019s biology and clinical implications. Curr Opin Lipidol 27(3):274\u2013281","journal-title":"Curr Opin Lipidol"},{"key":"8611_CR74","doi-asserted-by":"crossref","unstructured":"Paciullo F, et al. (2017) PCSK9 at the crossroad of cholesterol metabolism and immune function during infections. J Cell Physiol","DOI":"10.1002\/jcp.25767"},{"issue":"2","key":"8611_CR75","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1080\/13543784.2017.1272570","volume":"26","author":"AA Momtazi","year":"2017","unstructured":"Momtazi AA, Banach M, Sahebkar A (2017) PCSK9 inhibitors in sepsis: a new potential indication? Expert Opin Investig Drugs 26(2):137\u2013139","journal-title":"Expert Opin Investig Drugs"},{"key":"8611_CR76","doi-asserted-by":"crossref","unstructured":"Momtazi AA, et al. (2017) PCSK9 and diabetes: is there a link? Drug Discovery Today","DOI":"10.1016\/j.drudis.2017.01.006"},{"key":"8611_CR77","doi-asserted-by":"crossref","unstructured":"Momtazi AA, Banach M, and Sahebkar A (2017) PCSK9 inhibitors in sepsis: a new potential indication?, Taylor & Francis","DOI":"10.1080\/13543784.2017.1272570"},{"issue":"2","key":"8611_CR78","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M et al (2003) Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34(2):154\u2013156","journal-title":"Nat Genet"},{"issue":"2","key":"8611_CR79","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","volume":"37","author":"J Cohen","year":"2005","unstructured":"Cohen J et al (2005) Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 37(2):161\u2013165","journal-title":"Nat Genet"},{"issue":"12","key":"8611_CR80","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC et al (2006) Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 354(12):1264\u20131272","journal-title":"N Engl J Med"},{"issue":"3","key":"8611_CR81","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1086\/507488","volume":"79","author":"Z Zhao","year":"2006","unstructured":"Zhao Z et al (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79(3):514\u2013523","journal-title":"Am J Hum Genet"},{"issue":"2","key":"8611_CR82","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","volume":"193","author":"AJ Hooper","year":"2007","unstructured":"Hooper AJ et al (2007) The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis 193(2):445\u2013448","journal-title":"Atherosclerosis"},{"issue":"16","key":"8611_CR83","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","volume":"372","author":"JG Robinson","year":"2015","unstructured":"Robinson JG et al (2015) Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1489\u20131499","journal-title":"N Engl J Med"},{"issue":"16","key":"8611_CR84","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","volume":"372","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS et al (2015) Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372(16):1500\u20131509","journal-title":"N Engl J Med"},{"key":"8611_CR85","doi-asserted-by":"crossref","unstructured":"Sabatine MS, et al. (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med","DOI":"10.1056\/NEJMoa1615664"},{"issue":"3","key":"8611_CR86","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/14712598.2012.748743","volume":"13","author":"AJ Hooper","year":"2013","unstructured":"Hooper AJ, Burnett JR (2013) Anti-PCSK9 therapies for the treatment of hypercholesterolemia. Expert Opin Biol Ther 13(3):429\u2013435","journal-title":"Expert Opin Biol Ther"},{"issue":"1","key":"8611_CR87","doi-asserted-by":"crossref","first-page":"40","DOI":"10.7326\/M14-2957","volume":"163","author":"EP Navarese","year":"2015","unstructured":"Navarese EP et al (2015) Effects of proprotein convertase subtilisin\/kexin type 9 antibodies in adults with hypercholesterolemia. A systematic review and meta-analysis effects of PCSK9 antibodies in adults with hypercholesterolemia. Ann Intern Med 163(1):40\u201351","journal-title":"Ann Intern Med"},{"issue":"1","key":"8611_CR88","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","volume":"13","author":"X-L Zhang","year":"2015","unstructured":"Zhang X-L et al (2015) Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med 13(1):123","journal-title":"BMC Med"},{"issue":"7","key":"8611_CR89","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.2016.11004","volume":"316","author":"DS Kazi","year":"2016","unstructured":"Kazi DS et al (2016) Cost-effectiveness of PCSK9 inhibitor therapy in patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease. JAMA 316(7):743\u2013753","journal-title":"JAMA"},{"issue":"5","key":"8611_CR90","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1073\/pnas.0707594105","volume":"105","author":"RF Place","year":"2008","unstructured":"Place RF et al (2008) MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci 105(5):1608\u20131613","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"8611_CR91","first-page":"5978","volume":"8","author":"T Zambrano","year":"2015","unstructured":"Zambrano T et al (2015) Impact of 3\u2019UTR genetic variants in PCSK9 and LDLR genes on plasma lipid traits and response to atorvastatin in Brazilian subjects: a pilot study. Int J Clin Exp Med 8(4):5978","journal-title":"Int J Clin Exp Med"},{"issue":"2","key":"8611_CR92","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11883-014-0475-4","volume":"17","author":"M-A Cornier","year":"2014","unstructured":"Cornier M-A, Eckel RH (2014) Non-traditional dosing of statins in statin-intolerant patients\u2014is it worth a try? Current Atherosclerosis Reports 17(2):475","journal-title":"Current Atherosclerosis Reports"},{"issue":"4","key":"8611_CR93","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.tcm.2014.10.015","volume":"25","author":"JB Finkel","year":"2015","unstructured":"Finkel JB, Duffy D (2015) 2013 ACC\/AHA cholesterol treatment guideline: paradigm shifts in managing atherosclerotic cardiovascular disease risk. Trends in Cardiovascular Medicine 25(4):340\u2013347","journal-title":"Trends in Cardiovascular Medicine"},{"key":"8611_CR94","doi-asserted-by":"crossref","unstructured":"Raal FJ, Blom DJ Anacetrapib in familial hypercholesterolaemia: pros and cons. Lancet 385(9983):2124\u20132126","DOI":"10.1016\/S0140-6736(14)62315-1"},{"issue":"4","key":"8611_CR95","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jacl.2016.02.018","volume":"10","author":"FJ Raal","year":"2016","unstructured":"Raal FJ et al (2016) Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia. Journal of clinical lipidology 10(4):860\u2013869","journal-title":"Journal of clinical lipidology"},{"issue":"5","key":"8611_CR96","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2217\/clp.14.43","volume":"9","author":"MP McGowan","year":"2014","unstructured":"McGowan MP, Moriarty PM, Backes JM (2014) The effects of mipomersen, a second-generation antisense oligonucleotide, on atherogenic (apoB-containing) lipoproteins in the treatment of homozygous familial hypercholesterolemia. Clinical Lipidology 9(5):487\u2013503","journal-title":"Clinical Lipidology"},{"issue":"9","key":"8611_CR97","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1161\/CIRCULATIONAHA.113.001292","volume":"129","author":"DJ Rader","year":"2014","unstructured":"Rader DJ, Kastelein JJP (2014) Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 129(9):1022\u20131032","journal-title":"Circulation"},{"key":"8611_CR98","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.atherosclerosissup.2015.02.005","volume":"18","author":"I Gouni-Berthold","year":"2015","unstructured":"Gouni-Berthold I, Berthold HK (2015) Mipomersen and lomitapide: two new drugs for the treatment of homozygous familial hypercholesterolemia. Atheroscler Suppl 18:28\u201334","journal-title":"Atheroscler Suppl"},{"issue":"2","key":"8611_CR99","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.atherosclerosissup.2014.07.005","volume":"15","author":"M Cuchel","year":"2014","unstructured":"Cuchel M, Blom DJ, Averna MR (2014) Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia. Atheroscler Suppl 15(2):33\u201345","journal-title":"Atheroscler Suppl"},{"issue":"5","key":"8611_CR100","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1194\/jlr.M025130","volume":"53","author":"K Dai","year":"2012","unstructured":"Dai K, Hussain MM (2012) NR2F1 disrupts synergistic activation of the MTTP gene transcription by HNF-4\u03b1 and HNF-1\u03b1. J Lipid Res 53(5):901\u2013908","journal-title":"J Lipid Res"},{"issue":"2","key":"8611_CR101","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1194\/jlr.M400371-JLR200","volume":"46","author":"V Sheena","year":"2005","unstructured":"Sheena V et al (2005) Transcriptional regulation of human microsomal triglyceride transfer protein by hepatocyte nuclear factor-4\u03b1. J Lipid Res 46(2):328\u2013341","journal-title":"J Lipid Res"},{"issue":"44","key":"8611_CR102","doi-asserted-by":"crossref","first-page":"45685","DOI":"10.1074\/jbc.M404255200","volume":"279","author":"H Hirokane","year":"2004","unstructured":"Hirokane H et al (2004) Bile acid reduces the secretion of very low density lipoprotein by repressing microsomal triglyceride transfer protein gene expression mediated by hepatocyte nuclear factor-4. J Biol Chem 279(44):45685\u201345692","journal-title":"J Biol Chem"},{"issue":"6","key":"8611_CR103","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/acel.12135","volume":"12","author":"SE Choi","year":"2013","unstructured":"Choi SE et al (2013) Elevated microRNA-34a in obesity reduces NAD+ levels and SIRT1 activity by directly targeting NAMPT. Aging Cell 12(6):1062\u20131072","journal-title":"Aging Cell"},{"issue":"1","key":"8611_CR104","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1743-7075-9-14","volume":"9","author":"MM Hussain","year":"2012","unstructured":"Hussain MM et al (2012) Multiple functions of microsomal triglyceride transfer protein. Nutrition & metabolism 9(1):14","journal-title":"Nutrition & metabolism"},{"issue":"1","key":"8611_CR105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1194\/jlr.R200014-JLR200","volume":"44","author":"MM Hussain","year":"2003","unstructured":"Hussain MM, Shi J, Dreizen P (2003) Microsomal triglyceride transfer protein and its role in apoB-lipoprotein assembly. J Lipid Res 44(1):22\u201332","journal-title":"J Lipid Res"},{"issue":"12","key":"8611_CR106","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1016\/j.bbalip.2016.02.020","volume":"1861","author":"L Zhou","year":"2016","unstructured":"Zhou L et al (2016) MicroRNAs regulating apolipoprotein B-containing lipoprotein production. Biochimica et Biophysica Acta (BBA)-molecular and cell biology of lipids 1861(12):2062\u20132068","journal-title":"Biochimica et Biophysica Acta (BBA)-molecular and cell biology of lipids"},{"issue":"11","key":"8611_CR107","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1161\/01.ATV.0000094410.66558.9A","volume":"23","author":"AK Soutar","year":"2003","unstructured":"Soutar AK, Naoumova RP, Traub LM (2003) Genetics, clinical phenotype, and molecular cell biology of autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 23(11):1963\u20131970","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Clinical Reviews in Allergy & Immunology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12016-017-8611-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-017-8611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-017-8611-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T05:42:14Z","timestamp":1602135734000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12016-017-8611-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,22]]},"references-count":107,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["8611"],"URL":"https:\/\/doi.org\/10.1007\/s12016-017-8611-x","relation":{},"ISSN":["1080-0549","1559-0267"],"issn-type":[{"value":"1080-0549","type":"print"},{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,22]]}}}